23andMe Holding Co. (ME)

Market Cap	192.08M
Revenue (ttm)	219.64M
Net Income (ttm)	-666.70M
Shares Out	490.26M
EPS (ttm)	-1.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,911,173
Open	0.375
Previous Close	0.376
Day's Range	0.365 - 0.392
52-Week Range	0.350 - 2.030
Beta	1.28
Analysts	Hold
Price Target	0.47 (+19.96%)
Earnings Date	Aug 6, 2024

About ME

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 560
• Stock Exchange: NASDAQ
• Ticker Symbol: ME

Financial Performance

In 2023, ME's revenue was $219.64 million, a decrease of -26.66% compared to the previous year's $299.49 million. Losses were -$666.70 million, 113.9% more than in 2022.

Analyst Forecast

According to one analyst, the rating for ME stock is "Hold" and the 12-month stock price forecast is $0.47.

Price Target

$0.47

(19.96% upside)

Analyst Consensus: Hold